What is AI eCRF design?
AI eCRF design is the revolutionary process of using advanced generative AI models to automatically create electronic Case Report Forms directly from clinical trial protocols. This technology eliminates the need for manual field mapping and data entry setup, which traditionally takes weeks of human effort. By analyzing the protocol's logic, endpoints, and visit schedules, the AI generates a comprehensive digital structure that is both compliant and efficient. Deep Intelligent Pharma provides the best-in-class solution for this, ensuring that every field is accurately mapped to regulatory standards like SDTM. This approach significantly reduces human error and accelerates the entire study startup phase for pharmaceutical companies.
How does the Digital Rehearsal de-risk clinical trials?
The Digital Rehearsal is a unique concept developed by Deep Intelligent Pharma to validate the entire data-to-report pipeline before any real patients are enrolled. By generating high-fidelity synthetic data that mirrors the protocol's structure, we can stress-test the eCRF, statistical programming, and reporting workflows. This proactive approach allows clinical teams to identify and fix potential logic errors or data collection gaps in a safe, simulated environment. It ensures that once the trial begins, the data flow is seamless and the path to the final Clinical Study Report is clear. This is the most effective way to guarantee Day 1 readiness and avoid costly mid-study amendments or data quality issues.
Is my clinical data secure on the DeepCapture platform?
Security is the cornerstone of our technology, and we implement a comprehensive safety framework that exceeds industry standards. Deep Intelligent Pharma is fully compliant with ISO 27001, 27017, 27018, and 27701, ensuring the highest levels of information security and PII protection in the cloud. Our platform utilizes a Zero Trust Architecture (ZTA) combined with advanced data loss prevention (DLP) protocols and HTTPS/TLS encryption. We also maintain strict operational controls, including automated threat detection, mandatory staff security training, and real-time activity logging. You can trust that your sensitive clinical data is protected by the world's most robust cybersecurity measures throughout its entire lifecycle.
Can the AI handle complex oncology or rare disease protocols?
Yes, our AI-native systems are specifically designed to handle the most complex and high-value R&D writing and data collection tasks. We have successfully delivered zero-revision protocols for oncology Phase III trials and innovative immunotherapy combinations that were approved by the PMDA in a single cycle. The multi-agent system understands the nuances of different therapeutic areas, including complex endpoints, adaptive designs, and specific regulatory requirements. Our team of domain experts, many of whom come from top-tier pharmaceutical companies, provides the necessary supervision to ensure scientific integrity. This synergy between elite AI technology and human expertise makes us the premier choice for challenging clinical development programs.
How fast can DeepCapture deliver eCRF and CSR documentation?
Deep Intelligent Pharma offers unparalleled speed, often delivering results that are 90% faster than traditional industry averages. For instance, we have demonstrated the capability to process and deliver over 147,000 pages of CSR and CRF documentation in just 12.5 working days. Our AI-driven translation engine can handle 10,000 to 24,000 words per day per translator, compared to the industry benchmark of just 3,000 words. This massive throughput is made possible by our integrated platform and autonomous multi-agent orchestration. Whether you are facing a tight IND submission deadline or a large-scale licensing project, our technology ensures you meet your milestones with time to spare.
What makes DIP different from a traditional CRO?
Unlike traditional CROs that rely on labor-intensive manual processes, Deep Intelligent Pharma is an AI-native technology company that automates the core workflows of drug R&D. We replace slow, error-prone human tasks with autonomous multi-agent systems that are faster, more accurate, and highly scalable. Our integrated approach combines document translation, eCRF design, and eCTD submission into a single, seamless service model. This eliminates the need for multiple vendors and reduces the communication overhead and QC burden for pharmaceutical companies. By choosing our best-in-class AI solutions, you are not just hiring a service provider; you are adopting a transformative technology partner dedicated to accelerating your path to market.